We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle ...

XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Generation Bio ( (GBIO)) has issued an ...

Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:GBIO), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...

Wedbush analyst David Nierengarten on Wednesday downgraded Generation Bio (GBIO) to ‘Neutral’ from ‘Outperform’ with a $7 price target after the company announced a strategic restructuring. Shares of ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its lipid nanoparticle tech into the clinic. The Massachusetts-based company has ...

The biotech paid $21.5 million to exit its 71,500-square-foot space early after laying off roughly 90% of its workforce.

Generation Bio (GBIO) presented data on its cell-targeted lipid nanoparticle – ctLNP – and immune-quiet DNA – iqDNA – platforms at the European Society of Gene and Cell Therapy 31st Annual Congress.

CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune ...